Hexa Histidine-Tagged Recombinant Human Cytoglobin Deactivates Hepatic Stellate Cells and Inhibits Liver Fibrosis by Scavenging Reactive Oxygen Species

Dat, N. Q. Thuy, L. T. T. Hieu, V. N. Hai, H. Hoang, D. V. Thi Thanh Hai, N. Thuy, T. T. V. Komiya, T. Rombouts, K. Dong, M. P. Hanh, N. V. Hoang, T. H. Sato-Matsubara, M. Daikoku, A. Kadono, C. Oikawa, D. Yoshizato, K. Tokunaga, F. Pinzani, M. Kawada, N.
Hepatology. 2021 Jun;73(6):2527-2545. doi: 10.1002/hep.31752. Epub 2021 May 22.

Bile acid dysmetabolism in the gut-microbiota-liver axis under hepatitis C virus infection

Inoue, T. Funatsu, Y. Ohnishi, M. Isogawa, M. Kawashima, K. Tanaka, M. Moriya, K. Kawaratani, H. Momoda, R. Iio, E. Nakagawa, H. Suzuki, Y. Matsuura, K. Fujiwara, K. Nakajima, A. Yoshiji, H. Nakayama, J. Tanaka, Y.

Liver Int. 2021 Aug 19. doi: 10.1111/liv.15041.

HBx-induced degradation of Smc5/6 complex impairs homologous recombination-mediated repair of damaged DNA

Sekiba, K. Otsuka, M. Funato, K. Miyakawa, Y. Tanaka, E. Seimiya, T. Yamagami, M. Tsutsumi, T. Okushin, K. Miyakawa, K. Ryo, A. Koike, K.

J Hepatol. 2021 Aug 25. pii: S0168-8278(21)02005-5. doi: 10.1016/j.jhep.2021.08.010.

Infection courses, virological features and IFN-alpha responses of HBV genotypes in cell culture and animal models

Zhang, M. Zhang, Z. Imamura, M. Osawa, M. Teraoka, Y. Piotrowski, J. Ishida, Y. Sozzi, V. Revill, P. A. Saito, T. Chayama, K. Liang, T. J.

J Hepatol. 2021 Aug 4. pii: S0168-8278(21)01960-7. doi: 10.1016/j.jhep.2021.07.030.

Chimeric Mouse With Humanized Liver Is an Appropriate Animal Model to Investigate Mode of Action for Porphyria-Mediated Hepatocytotoxicity

Toxicol Pathol. 2021 Jul 9:1926233211027474. doi: 10.1177/01926233211027474.

Eguchi, A. Fukunaga, S. Ogata, K. Kushida, M. Asano, H. Cohen, S. M. Sukata, T.

Application of humanized mice to toxicology studies: Evaluation of the human relevance of the mode of action for rodent liver tumor formation by activators of the constitutive androstane receptor (CAR)

Journal Toxicologic Pathology 2021; 34(4): 283-297. doi: https://doi.org/10.1293/tox.2021-0027

Tomoya Yamada

Critical evaluation of the human relevance of the mode of action for rodent liver tumor formation by activators of the constitutive androstane receptor (CAR)

Yamada, T. Cohen, S. M. Lake, B. G.

Crit Rev Toxicol. 2021;51(5):373-394. doi:10.1080/10408444.2021.1939654. Epub 2021 Jul 15.

MafF is an antiviral host factor that suppresses transcription from Hepatitis B Virus core promoter

Marwa K. Ibrahim, Tawfeek H. Abdelhafez, Junko S. Takeuchi, Kosho Wakae, Masaya Sugiyama, Masataka Tsuge, Masahiko Ito, Koichi Watashi, Mohamed El. Kassas, Takanobu Kato, Asako Murayama, Tetsuro Suzuki, Kazuaki Chayama, Kunitada Shimotohno, Masamichi Muramatsu, Hussein H. Aly, Takaji Wakita

J Virol. 2021 Jul 12;95(15):　e0076721. doi: 10.1128/JVI.00767-21. Epub 2021 Jul 12.

Cholesterol-binding translocator protein TSPO regulates steatosis and bile acid synthesis in nonalcoholic fatty liver disease

Li, Y. Chen, L. Li, L. Sottas, C. Petrillo, S. K. Lazaris, A. Metrakos, P. Wu, H. Ishida, Y. Saito, T. Golden-Mason, L. Rosen, H. R. Wolff, J. J. Silvescu, C. I. Garza, S. Cheung, G. Huang, T. Fan, J. Culty, M. Stiles, B. Asahina, K. Papadopoulos, V.

iScience. 2021 May 1;24(5):102457. doi: 10.1016/j.isci.2021.102457.

Loss of lysophosphatidic acid receptor 1 in hepatocytes reduces steatosis via down-regulation of CD36

Lua, I. Balog, S. Yanagi, A. Tateno, C. Asahina, K.

Prostaglandins Other Lipid Mediat. 2021 Jun 17:106577. doi: 10.1016/j.prostaglandins.2021.106577.

Novel drug resistance-associated substitutions against pibrentasvir emerged in genotype 1b hepatitis C virus-infected human hepatocyte transplanted mice

Ohya, K. Imamura, M. Teraoka, Y. Uchida, T. Fujino, H. Nakahara, T. Ono, A. Murakami, E. Yamauchi, M. Kawaoka, T. Miki, D. Tsuge, M. Abe-Chayama, H. Hayes, C. N. Aikata, H. Ishida, Y. Tateno, C. Song, H. Miyayama, Y. Hijikata, M. Chayama, K.

Biochem Biophys Res Commun. 2021 Jun 25;559:78-83. doi: 10.1016/j.bbrc.2021.04.062. Epub 2021 Apr 29.

Prediction of human pharmacokinetics for low-clearance compounds using pharmacokinetic data from chimeric mice with humanized livers

Yoshida, K. Doi, Y. Iwazaki, N. Yasuhara, H. Ikenaga, Y. Shimizu, H. Nakada, T. Watanabe, T. Tateno, C. Sanoh, S.Kotake, Y.

Clin Transl Sci. 2021 Jun 3. doi: 10.1111/cts.13070.

Safety and Efficacy of Avaren-Fc Lectibody Targeting HCV High-Mannose Glycans in a Human Liver Chimeric Mouse Model

Dent, M. Hamorsky, K. Vausselin, T. Dubuisson, J. Miyata, Y. Morikawa, Y. Matoba, N.
Cell Mol Gastroenterol Hepatol. 2021;11(1):185-198. doi: 10.1016/j.jcmgh.2020.08.009. Epub 2020 Aug 27.

Interferon signaling suppresses the unfolded protein response and induces cell death in hepatocytes accumulating hepatitis B surface antigen

Baudi, I. Isogawa, M. Moalli, F. Onishi, M. Kawashima, K. Ishida, Y. Tateno, C. Sato, Y. Harashima, H. Ito, H. Ishikawa, T. Wakita, T. Iannacone, M. Tanaka, Y.
PLoS Pathog. 2021 May 12;17(5):e1009228. doi: 10.1371/journal.ppat.1009228.

Understanding hepatitis B virus dynamics and the antiviral effect of interferon-alpha treatment in humanized chimeric mice

Reinharz, V. Ishida, Y. Tsuge, M. Durso-Cain, K. Chung, T. L. Tateno, C. Perelson, A. S. Uprichard, S. L. Chayama, K. Dahari, H.
J Virol. 2021 Apr 28. pii: JVI.00492-20. doi: 10.1128/JVI.00492-20.

Dual Agonist of Farnesoid X Receptor and G Protein-coupled Receptor TGR5 Inhibits Hepatitis B Virus Infection in Vitro and in Vivo

Ito, K. Okumura, A. S. Takeuchi J Watashi, K. Inoue, R. Yamauchi, T. Sakamoto, K. Yamashita, Y. Iguchi, Y. Une, M. Wakita, T. Umezawa, K. Yoneda, M.

Hepatology. 2021 Jan 12. doi: 10.1002/hep.31712.

Evaluation of the Utility of PXB Chimeric Mice for Predicting Human Liver Partitioning of Hepatic Organic Anion-Transporting Polypeptide Transporter Substrates

Feng, B. Pemberton, R. Dworakowski, W. Ye, Z. Zetterberg, C. Wang, G. Morikawa, Y. Kumar, S.

Drug Metab Dispos. 2021 Mar;49(3):254-264. doi: 10.1124/dmd.120.000276. Epub 2020 Dec 29.

Development of an in vivo delivery system for CRISPR/Cas9-mediated targeting of hepatitis B virus cccDNA

Kayesh, M. E. H. Amako, Y. Hashem, M. A. Murakami, S. Ogawa, S. Yamamoto, N. Hifumi, T. Miyoshi, N. Sugiyama, M. Tanaka, Y. Mizokami, M. Kohara, M. Tsukiyama-Kohara, K.

Virus Res. 2020 Oct 10;290:198191. doi: 10.1016/j.virusres.2020.198191.

Fluoxazolevir inhibits hepatitis C virus infection in humanized chimeric mice by blocking viral membrane fusion

Ma, C. D. Imamura, M. Talley, D. C. Rolt, A. Xu, X. Wang, A. Q. Le, D. Uchida, T. Osawa, M. Teraoka, Y. Li, K. Hu, X. Park, S. B. Chalasani, N. Irvin, P. H. Dulcey, A. E. Southall, N. Marugan, J. J. Hu, Z. Chayama, K. Frankowski, K. J. Liang, T. J.

Nat Microbiol. 2020 Aug 31. doi: 10.1038/s41564-020-0781-2.

Detection of acute toxicity of aflatoxin B1 to human hepatocytes in vitro and in vivo using chimeric mice with humanized livers

Ishida, Y. Yamasaki, C. Iwanari, H. Yamashita, H. Ogawa, Y. Yanagi, A. Furukawa, S. Kojima, Y. Chayama, K. Kamiie, J. Tateno, C.

PLoS One. 2020 Sep 23;15(9):e0239540. doi: 10.1371/journal.pone.0239540.